Product Spotlight

What is Levothyroxine Sodium T4?

Not always called levothyroxine sodium, levothyroxine is something we sell on gurupeptides.com so we figured we should spend a little time talking about it so that you can make your purchase without any misconceptions.  Levothyroxine sodium has a variety of shorter names, mostly for simplicity’s sake. We like to refer to it and market it is Levothyroxine T4 while other people in the industry call it L-Thyroxine, Levo T, Levothroid, Levoxine, and simply LT4.  Regardless of what the name is that levothyroxine sodium is marketed under, it is almost always the same exact base product. – Though quality and purity may differ from source to source.

So… What is Levothyroxine T4?

Levothyroxine T4 is basically a synthetic, manufactured version of thyroxine.  Thyroxine is the hormone that our bodies manufacture in the thyroid glands. Technically, it is one of two hormones created by the thyroids, the other being triiodothyronine.  Both hormones interact with almost all the cells in your body, establishing metabolic rate and regulate protein synthesis. Thyroxine has a much longer half-life than triiodothyronine and is more important when it comes to metabolism regulation, which is why most companies try to manufacture synthetic thyroxine instead of synthetic triiodothyronine.

Well Researched and Proven Safe

A stark contrast to many of the products that we manufacture and sell, Levothyroxine T4 was first created way back in 1927.  Even then it was presumed to be useful in the treatment of hypothyroidism.  According to MayoClinic, hypothyroidism is a result of the human body not producing enough of the aforementioned hormones.  The effects include obesity and subsequently, other serious issues like blood pressure problems, diabetes, and even increase risk of heart disease.

1 King, Tekoa L, and Mary C Brucker. “Pharmacology for Women’s Health.” Google Books, https://books.google.com/books?id=E9qVyrNPsBkC&pg=PA544#v=onepage&q=1927&f=false.

2 “Hypothyroidism (Underactive Thyroid).” Mayo Clinic, Mayo Foundation for Medical Education and Research, 4 Dec. 2018, www.mayoclinic.org/diseases-conditions/hypothyroidism/symptoms-causes/syc-20350284.

For better than 50 years, Levothyroxine has been used to treat hypothyroidism.  This study completed at the end of 2011 deep dives the efficacy and stresses just how safe it is.  The complete lack of side effects continues to ensure Levothyroxine will be prescribed as the go-to treatment method.

Over the past couple of decades, we’ve made strides in proving the potential use for levothyroxine in diabetes and patients struggling with heart disease:

Early 2004 – “LT4 therapy can be beneficial in diminishing lipid abnormalities…”   Finding medicinal solutions for ailments in patients that already struggle with weak arteries or coronary artery disease has always been a struggle.  Thankfully, Levothyroxine doesn’t fall flat in this regard.

April 2016 – Studies showing favorable results for levothyroxine therapy in patients with diabetes start to surface.  This opens the door to a whole new realm of research.

November 2017 – Type 1 diabetes in mice is no issue when it comes to levothyroxine…  In fact, the study found that Levothyroxine enhanced the glucose clearance, helping with the sugar problem rather than causing a hinderance!  The research group claimed that it was safe to say that we could start exploring the therapeutic benefits in patients with type 1 diabetes.

July 2018 – A very recent study found similar results to the previous study completed in 2017, with one very key difference.  The study concluded that there is substantial “efficacy and safety of low-dose TH therapy” for people suffering from Type 2 diabetes!

3 Ali J Chakera, Simon HS Pearce, Bijay Vaidya. “Treatment for primary hypothyroidism: current approaches and future possibilities.” Drug Des Devel Ther., U.S. National Library of Medicine, 2011, Dec 22, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3267517/.

4 Fadeyev, V V, et al. “Levothyroxine Replacement Therapy in Patients with Subclinical Hypothyroidism and Coronary Artery Disease.” Current Neurology and Neuroscience Reports., U.S. National Library of Medicine, www.ncbi.nlm.nih.gov/pubmed/16524858.

5 Harbuwono, D S, et al. “Improvement of Metabolic Parameters Resulted from Levothyroxine Therapy in Hypothyroid Type 2 Diabetes Mellitus Patient.” Current Neurology and Neuroscience Reports., U.S. National Library of Medicine, Apr. 2016, www.ncbi.nlm.nih.gov/pubmed/27550885.

6 Bruinstroop, E, et al. “Low-Dose Levothyroxine Reduces Intrahepatic Lipid Content in Patients With Type 2 Diabetes Mellitus and NAFLD.” Current Neurology and Neuroscience Reports., U.S. National Library of Medicine, 1 July 2018, www.ncbi.nlm.nih.gov/pubmed/29718334.

Leave a Reply